Welcome to our dedicated page for Omnicell Com news (Ticker: OMCL), a resource for investors and traders seeking the latest updates and insights on Omnicell Com stock.
Omnicell, Inc. (NASDAQ: OMCL) develops healthcare technology for autonomous medication management across pharmacy and nursing care settings. Its updates cover financial results, product bookings, recurring revenue, connected-device demand, and product launches such as Omnicell Titan XT and the OmniSphere platform.
Company news also includes healthcare conference presentations, customer engagement programs, clinical leadership roles, and innovation updates tied to automation, AI-enabled intelligence, software workflows, data analytics, and expert services for medication management in healthcare facilities.
Omnicell (NASDAQ:OMCL) reported fiscal year and fourth quarter 2025 results on February 5, 2026, with FY2025 total revenue $1.185B (up 7% YoY) and Q4 revenue $314M (up 2% YoY). The company launched the new Titan XT automated dispensing system and reported ARR $635.6M.
GAAP net loss for Q4 2025 was $2M (loss of $0.05 per diluted share); FY2025 GAAP net income was $2M ($0.04 per diluted share). FY non-GAAP net income was $75M ($1.62 per diluted share). 2026 guidance includes total revenue $1.215B–$1.255B and ARR $680M–$700M.
Omnicell (Nasdaq:OMCL) will release fourth quarter and full year 2025 financial results before market open on Thursday, February 5, 2026. Management will host a conference call and webcast to discuss results at 8:30 a.m. ET the same day.
Investors can join by dialing (800) 715-9871 (U.S.) or (646) 307-1963 (international) using Conference ID 4203777. A live and archived webcast will be available on Omnicell's Investor Relations events page at https://ir.omnicell.com/events-and-presentations/.
Omnicell (NASDAQ:OMCL) launched Titan XT, an enterprise automated dispensing system powered by OmniSphere, the company’s cloud-based, HITRUST-certified medication management platform. Titan XT extends OmniSphere to nursing care areas, aiming to unify inventory, enable a global formulary, and support perpetual inventory across large health systems.
Key operational points: a customer reported ~70% time savings for cabinet restocking; Titan XT is available for purchase in the United States now; international availability is anticipated later in 2026, and ongoing OmniSphere releases begin in early 2027.
Omnicell (Nasdaq: OMCL) will host an Innovation Update and an investor Q&A session at the ASHP Midyear Clinical Meeting & Exhibition in Las Vegas on Monday, December 8, 2025.
The Innovation Update is in person only at Booth #1241 at 3:00 PM PT. The Q&A session is in person and will be webcast at 4:00 PM PT, with a live and archived webcast available on Omnicell's investor website.
Omnicell (Nasdaq: OMCL) will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 1:00 p.m. ET.
Live and archived webcasts of the presentation will be available via the company’s investor relations site at https://ir.omnicell.com/events-and-presentations/.
Omnicell (Nasdaq: OMCL) announced that its Specialty Pharmacy Services business earned URAC Health Care Management Certification, effective Oct 1, 2025 through Oct 1, 2028. The certification recognizes enterprise-grade clinical oversight, operational governance, and specialty pharmacy support under URAC's rigorous standards for clinical governance, risk management, and performance improvement.
Omnicell says the URAC-certified service model enables health systems to launch and scale in-house specialty pharmacy and 340B programs under their own licenses while retaining brand, clinical, and financial ownership.
Summary not available.
Omnicell (Nasdaq: OMCL) will release its third quarter 2025 financial results before market open on Thursday, October 30, 2025. The company will host a conference call and webcast to review results at 8:30 a.m. ET the same day. Dial-in numbers are (800) 715-9871 (U.S.) and (646) 307-1963 (international) with Conference ID 3131192. A live and archived webcast link will be available on the Investor Relations events page at https://ir.omnicell.com/events-and-presentations/.
Omnicell (Nasdaq: OMCL) has appointed Baird Radford as Executive Vice President and Chief Financial Officer, effective August 26, 2025. Radford, who brings over 30 years of healthcare and technology experience, succeeds Nchacha Etta, who will remain in an advisory role through November 2025.
Radford joins from Allakos Inc., where he served as CFO managing strategic finance and investor relations. His previous roles include senior positions at Aimmune Therapeutics, HeartFlow, Intuitive Surgical, eBay, and PricewaterhouseCoopers. The appointment aligns with Omnicell's transformation into a digitally-enabled medication management technology company.
Omnicell (NASDAQ:OMCL) reported strong Q2 2025 financial results, exceeding previous guidance. Total revenues reached $291 million, up 5% year-over-year, with GAAP net income of $6 million ($0.12 per share) and non-GAAP net income of $21 million ($0.45 per share).
The company maintains a solid balance sheet with $399 million in cash and equivalents, while operating cash flow was $43 million. Notable achievements include the launch of MedVision and MedTrack/MedTrack-OR solutions, HITRUST CSF i1 certification for OmniSphere, and the opening of a new Innovation Lab in Austin.
Based on strong H1 2025 performance, Omnicell raised its full-year 2025 guidance, projecting total revenues of $1.13-1.16 billion and non-GAAP EPS of $1.40-1.65.